Information Provided By:
Fly News Breaks for February 21, 2018
SRPT
Feb 21, 2018 | 07:13 EDT
JPMorgan analyst Anupam Rama raised his price target for Sarepta Therapeutics to $75 from $63 and reiterates an Overweight rating on the shares. The stock closed yesterday down 2%, or $1.13, to $62.87. Sarepta has multiple important regulatory updates into mid-2018, including a U.S. regulatory update for golodirsen in the first half of 2018 and the Committee for Medicinal Products for Human Use's decision in mid-2018 for Exondys 51, Rama tells investors in a research note. He believes the stock's reward/risk profile is "very favorable" into the regulatory events, with potential upside of 55% in a best case scenario and downside of 15%-20% in a worst case scenario.
News For SRPT From the Last 2 Days
There are no results for your query SRPT